57.5% achieved remission
in 10 weeks1
From the pivotal trial1, NHS pilots2, and over 60,000 real-world users3, Flow has repeatedly been shown to support reducing depressive symptoms.
Results at 10 weeks from a multisite, double-blind placebo-controlled randomised superiority trial were statistically significant for both primary and secondary endpoints.
Flow achieved a 57.5% remission rate using the MADRS scale and was effective as both standalone and adjunctive therapy1.
The EMPOWER clinical trial also showed Flow can have an enhanced effect when supplemented with an antidepressant1. More research is needed to examine this further. This impact has also been reported in real-world cases.
Retrospective open-label data from 13,683 real-world users indicates that adherent individuals achieved early clinical improvement, with a positive shift in severity levels observed by Week 3 across all baseline cohorts4.
Everything you need to succeed
with Flow
Neuromodulation is an emerging field for many clinicians.
To ensure you are fully supported, we provide complimentary training, ongoing clinical support, and a demo device, allowing you to evaluate Flow firsthand.
References: 1. Woodham, R.D., Selvaraj, S., Lajmi, N. et al. Nat Med (2024). 2. Griffiths, C. et al. (2024). Open Journal of Depression. 13(02), 25–39. 3. Data on file. Flow Neuroscience Real-world reports. 4. Mu M., et al. J Affect Disord Reports. (2026)